文献速递炎症性肠病

培养的人肠道真菌近平滑念珠菌M2006B通过分泌无环倍半萜作为FXR激动剂减轻结肠炎

Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists.
PubMed 文献 · Gut · 2022-02-16

该研究从人粪便中培养肠道真菌,发现IBD患者中念珠菌属丰度显著升高;近平滑念珠菌M2006B在野生型、抗生素处理、无菌及IL10-/-小鼠中通过激活法尼醇X受体(FXR)显著减轻实验性结肠炎。M2006B的七种无环倍半萜(F1-F7)中,F4和F5作为新型FXR激动剂减轻小鼠结肠炎,该效应在Fxr-/-小鼠中得到确认。

要点

  • IBD患者肠道念珠菌属丰度显著高于对照。
  • 近平滑念珠菌M2006B通过激活FXR减轻多种小鼠结肠炎模型。
  • F4和F5是M2006B分泌的新型FXR激动剂,可减轻小鼠结肠炎。

核心结论

  • 近平滑念珠菌M2006B显著减轻小鼠结肠炎,F4和F5是其主要活性代谢物。
  • F4和F5通过选择性激活FXR有效治疗实验性结肠炎。
  • M2006B可能是治疗和预防IBD的有益肠道真菌。

研究设计与样本

  • 从人粪便中培养IBD中差异丰度的肠道真菌菌株,评估其对多种小鼠实验性结肠炎模型的影响。
  • 鉴定目标真菌分泌的生物活性代谢物,并在体外和体内研究其药理作用及潜在分子靶点。

主要发现

  • IBD患者中念珠菌属丰度显著升高。
  • 近平滑念珠菌M2006B在野生型、抗生素处理、无菌及IL10-/-小鼠中通过激活FXR显著减轻多种实验性结肠炎模型。
  • M2006B的七种无环倍半萜(F1-F7)中,F4和F5作为新型FXR激动剂减轻小鼠结肠炎。
  • M2006B及其代谢物通过特异性FXR激活对结肠炎的治疗效应在Fxr-/-小鼠中得到确认。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dysbiosis of the intestinal fungal community has been observed in inflammatory bowel disease (IBD); however, its potential role in IBD development and prevention remains unclear. Here, we explored the biological effects and molecular mechanisms of intestinal fungi isolated from human faeces on colitis in mice. DESIGN: Intestinal fungal strains with differential abundance in IBD were cultivated in human faeces and their effects on various mouse models of experimental colitis were evaluated. In addition, the bioactive metabolites secreted by the target fungus were accurately identified and their pharmacological effects and potential molecular targets were investigated in vitro and in vivo. RESULTS: The abundance of Candida spp was significantly higher in patients with IBD. After large-scale human intestinal fungal cultivation and functional analysis, Candida metapsilosis M2006B significantly attenuated various models of experimental colitis in wild-type, antibiotic-treated, germ-free, and IL10-/- mice by activating farnesoid X receptor (FXR). Among the seven acyclic sesquiterpenoids (F1-F7) identified as major secondary metabolites of M2006B, F4 and F5 attenuated colitis in mice by acting as novel FXR agonists. The therapeutic effects of M2006B and its metabolites on colitis via specific FXR activation were confirmed in Fxr -/- mice. CONCLUSION: This study revealed that C. metapsilosis M2006B significantly attenuated colitis in mice and identified two acyclic sesquiterpenoids (F4 and F5) as major active metabolites of M2006B. Notably, these metabolites were able to effectively treat experimental colitis by selectively activating FXR. Together, this study demonstrates that M2006B could be a beneficial intestinal fungus for treating and preventing IBD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Huo X, Li D, Wu F, et al. Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists. Gut. 2022. PMID: 35173042. doi:10.1136/gutjnl-2021-325413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。